GlassScriptPhysician profile
Allison K Rodgers
NPI 1568664092
$19,279.86
in general payments reported to CMS, 2019-2025
20 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,775 · 2020: $1,861 · 2021: $1,264 · 2022: $555 · 2023: $11K · 2024: $562 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $1,495 · Education: $80.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,250.00 |
| Food and Beverage | $1,494.59 |
| Education | $80.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $8,869.94 | 2019-2024 | Menopur, Endometrin, Fyremadel |
| Galen US INC | $5,545.56 | 2019-2021 | |
| Pfizer INC. | $2,450.00 | 2023 | |
| Abbvie INC. | $633.23 | 2019-2024 | Synthroid |
| Organon LLC | $525.26 | 2021-2025 | Pregnyl, Follistim Aq, Ganirelix Acetate |
| Emd Serono, INC. | $510.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $187.19 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $128.26 | 2022-2023 | Unithroid |
| Agile Therapeutics, INC. | $96.59 | 2021 | |
| Myovant Sciences INC. | $55.00 | 2022 | |
| Mission Pharmacal Company | $48.02 | 2019-2023 | Citranatal |
| Duchesnay USA Incorporated | $34.57 | 2019 | |
| Avion Pharmaceuticals | $32.65 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $31.53 | 2019 | |
| Medtronic, INC. | $28.09 | 2024 | Truclear |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meitheal Pharmaceuticals, INC. | $26.91 | 2024 | |
| Sumitomo Pharma America, INC. | $25.63 | 2023 | Myfembree |
| Exeltis, USA INC. | $22.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.51 | 2022 | |
| Ibsa Pharma INC. | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Rodgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.